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Summary
Background The leucine-rich repeat kinase 2 gene (LRRK2) harbours highly penetrant mutations that are linked to 
familial parkinsonism. However, the extent of its polymorphic variability in relation to risk of Parkinson’s disease 
(PD) has not been assessed systematically. We therefore assessed the frequency of LRRK2 exonic variants in individuals 
with and without PD, to investigate the role of the variants in PD susceptibility.
Methods LRRK2 was genotyped in patients with PD and controls from three series (white, Asian, and Arab–Berber) 
from sites participating in the Genetic Epidemiology of Parkinson’s Disease Consortium. Genotyping was done for 
exonic variants of LRRK2 that were identiﬁ ed through searches of literature and the personal communications of 
consortium members. Associations with PD were assessed by use of logistic regression models. For variants that had 
a minor allele frequency of 0·5% or greater, single variant associations were assessed, whereas for rarer variants 
information was collapsed across variants. 
Findings 121 exonic LRRK2 variants were assessed in 15 540 individuals: 6995 white patients with PD and 
5595 controls, 1376 Asian patients and 962 controls, and 240 Arab–Berber patients and 372 controls. After exclusion 
of carriers of known pathogenic mutations, new independent risk associations were identiﬁ ed for polymorphic 
variants in white individuals (M1646T, odds ratio 1·43, 95% CI 1·15–1·78; p=0·0012) and Asian individuals 
(A419V, 2·27, 1·35–3·83; p=0·0011). A protective haplotype (N551K-R1398H-K1423K) was noted at a frequency 
greater than 5% in the white and Asian series, with a similar ﬁ nding in the Arab–Berber series (combined odds ratio 
0·82, 0·72–0·94; p=0·0043). Of the two previously reported Asian risk variants, G2385R was associated with disease 
(1·73, 1·20–2·49; p=0·0026), but no association was noted for R1628P (0·62, 0·36–1·07; p=0·087). In the 
Arab–Berber series, Y2189C showed potential evidence of risk association with PD (4·48, 1·33–15·09; p=0·012).
Interpretation The results for LRRK2 show that several rare and common genetic variants in the same gene can have 
independent eﬀ ects on disease risk. LRRK2, and the pathway in which it functions, is important in the cause and 
pathogenesis of PD in a greater proportion of patients with this disease than previously believed. These results will help 
discriminate those patients who will beneﬁ t most from therapies targeted at LRRK2 pathogenic activity.
Funding Michael J Fox Foundation and National Institutes of Health. 
Introduction
Parkinson’s disease (PD) is generally thought of as a 
late-onset sporadic disorder. Nevertheless, genetic 
insights are helping to deﬁ ne the molecular causes of 
PD and have provided new models for the development 
of neuro protective inter ventions. Mutations in the 
leucine-rich repeat kinase 2 gene (LRRK2) are now 
recognised as the most common genetic determinant of 
familial and sporadic PD.1 LRRK2 has 51 exons and 
encodes the 2527 aminoacid protein LRRK2, which has 
ﬁ ve conserved domains, including a Roc (Ras in complex 
proteins, Rab GTPase) domain and a catalytic core 
common to both tyrosine and serine-threonine kinases. 
Pathogenic LRRK2 variability has been identiﬁ ed by 
sequencing probands with familial parkinsonism, with 
results conﬁ rmed and occasionally extended within 
community or clinically-based patient–control series.2–6 
Seven deﬁ nite pathogenic LRRK2 mutations (encoding 
LRRK2 N1437H, R1441C, R1441G, R1441H, Y1699C, 
G2019S, and I2020T) have been described.7,8 These 
mutations can be relatively common in patients from 
some ethnic origins, but are rare in ethnically matched 
controls. LRRK2 R1441G has been identiﬁ ed in more 
than 8% of patients with PD originating from the 
Basque region of northern Spain,9 and LRRK2 G2019S 
has been reported in 30% of Arab–Berber patients 
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with PD.10,11 LRRK2 polymorphisms with more than 1% 
minor allele frequency have also been associated with 
PD in Asia, with the estimated attributable risk often 
dependent on ethnic origin. LRRK2 R1628P and 
G2385R have each been recorded in 3–4% of individuals 
who are of Chinese descent and roughly double the risk 
of PD.12–15 
However, most LRRK2 variants have not been 
systematically studied. LRRK2 might harbour more 
variants that are important determinants of PD 
pathogenicity and clinical risk. To address this possibility, 
with the Genetic Epidemiology of Parkinson’s Disease 
(GEO-PD) Consortium, we assessed the frequency of 
LRRK2 exonic variants in people with and without PD, and 
assessed the role of the variants in disease susceptibility.
Methods
Participants and procedures
All 35 GEO-PD sites (hospitals and centres), representing 
22 countries and six continents, were invited to 
participate in this study. Patients were diagnosed by use 
of either the Gelb or the UK Parkinson’s Disease Society 
Brain Bank criteria (the exclusion criterion of more than 
one aﬀ ected relative was not included).16,17 Controls at 
each site were healthy individuals who were not related 
to the patients; not all controls were given a detailed 
neurological examination but all were asked about any 
previous diagnosis or family history of a neurological 
disorder. All biological samples were gathered after 
ethics approval had been obtained from the Mayo Clinic 
Institutional Review Board Committee, and were used 
in accordance with the terms of the written informed 
consent provided by the participants.
LRRK2 exonic variants were identiﬁ ed through 
searches of available literature up to April 1, 2010, from 
personal communications with consortium members, 
and from in-house sequencing studies that had 
identiﬁ ed novel variants (unpublished data; table 1). 
DNA was sourced from blood and was stored in a –20°C 
freezer. All samples were de-identiﬁ ed with an 
anonymous code from each site and only a minimal 
clinical dataset.  Data were collected in batches but 
analysed as a single dataset. Genotyping was done on a 
MassArray iPLEX platform (Sequenom, San Diego, CA, 
USA) at the Mayo Clinic neurogenetics laboratory, FL, 
USA (except for the groups from Paris, France, and 
Antwerp, Belgium, who supplied genotype data and 
positive control genomic DNA2,3); all primer sequences 
are provided in the webappendix pp 1–4). Eight iPLEX 
variant combinations were used to incorporate 
123 LRRK2 coding variants (table 1). Positive control 
DNA was run for each variant; in the absence of a 
positive genomic control DNA, a synthetic positive 
control DNA sequence was generated by use of 
mismatch-primer PCR. A χ² test followed by Bonferroni 
correction was used to test for deviation from the 
Hardy–Weinberg equilibrium (HWE) in controls for 
Exon Accession number cDNA Amino acid Domain
chr12:38905228 1 ·· 28G>A E10K ··
chr12:38905349 1 rs2256408 149G>A R50H ··
chr12:38905627 2 rs72546335 155C>T S52F ··
chr12:38905696 2 rs75054132 224G>A A75A ··
chr12:38915703 4 rs33995463 356T>C L119P ··
chr12:38915711 4 rs41286468 364T>C L122L ··
chr12:38918058 5 rs10878245 457T>C L153L ··
chr12:38918147 5 rs35517158 546A>G K182K ··
chr12:38920612 6 rs112794616 632C>T A211V ··
chr12:38920663 6 rs56108242 683G>C C228S ··
chr12:38923625 7 rs28365216 713A>T N238I ··
chr12:38923737 7 rs72546315 824C>T H275H ··
chr12:38929923 8 rs17490713 867T>C N289N ··
chr12:38929949 8 rs57355477 893T>C A298A ··
chr12:38929992 8 rs41286466 936G>T A312A ··
chr12:38931342 9 rs78501232 1000G>A E334K ··
chr12:38931397 9 rs36016791 1055delC A352fsX357 ··
chr12:38931430 9 rs72546336 1088A>G N363S ··
chr12:38931438 9 rs113065049 1096G>A V366M ··
chr12:38933053 11 rs34594498 1256C>T A419V ··
chr12:38937411 12 rs35847451 1383C>T S461S ··
chr12:38939594 13 rs75711334 1464A>T L488L ··
chr12:38939673 13 rs34090008 1543insG P514fsX529 ··
chr12:38943875 14 rs35328937 1561A>G R521G ··
chr12:38943944 14 rs79996249 1630 A>G K544E ··
chr12:38943967 14 rs7308720 1653C>G N551K ··
chr12:38954669 15 rs77424631 1647G>A G558G ··
chr12:38958002 17 rs78154388 1987T>C S663P ··
chr12:38958037 17 rs72546319 2022A>C V674V ··
chr12:38958213 17 rs35611877 2198insA L708fsX718 Ankyrin
chr12:38958223 18 ·· 2134A>G M712V Ankyrin
chr12:38958236 18 ·· 2147C>T A716V Ankyrin
chr12:38958256 18 rs10878307 2167A>G I723V Ankyrin
chr12:38963966 19 rs34410987 2264C>T P755L Ankyrin
chr12:38964080 19 rs35173587 2378G>T R793M Ankyrin
chr12:38964130 19 rs72546337 2428A>G I810V Ankyrin
chr12:38964183 19 rs76890302 2481T>C S827S Ankyrin
chr12:38967530 20 ·· 2611A>G K871E ··
chr12:38973693 21 rs58559150 2769G>C Q923H ··
chr12:38973713 21 ·· 2789A>G Q930R ··
chr12:38974935 22 rs17519916 2830G>T D944Y ··
chr12:38974962 22 rs7966550 2857T>C L953L ··
chr12:38975535 23 rs75148313 2918G>A S973N ··
chr12:38975635 23 rs113217062 3018A>G I1006M LRR
chr12:38975638 23 rs55783828 3021C>T S1007S LRR
chr12:38978415 24 rs111341148 3200G>A R1067Q LRR
chr12:38978502 24 rs76535406 3287C>G S1096C LRR
chr12:38978548 24 rs78365431 3333G>T Q1111H LRR
chr12:38978557 24 rs35808389 3342A>G L1114L LRR
chr12:38979194 25 rs34805604 3364A>G I1122V LRR
chr12:38979281 25 rs74985840 3451G>A A1151T LRR
chr12:38979324 25 ·· 3494T>C L1165P LRR
(Continues on next page)
Articles
900 www.thelancet.com/neurology   Vol 10   October 2011
each site. Direct DNA sequencing was used to conﬁ rm 
genotyping for all variants with a frequency of less than 
0·3% (n<50 carriers).
Statistical analysis
All analyses were undertaken separately for the patients 
in the white, Asian, and Arab–Berber series. For 
common variants with a minor allele frequency of 0·5% 
or greater, single variant associations with PD were 
assessed by use of ﬁ xed-eﬀ ects logistic regression 
models, in which genotypes were dichotomised as 
presence versus absence of the minor allele (dominant 
model), because LRRK2 mutations cause an autosomal 
dominantly inherited form of PD and homozygotes for 
many of the variants are rare; additive models were also 
assessed. Models were adjusted for site in the white and 
Asian series. Sensitivity of results to the use of random-
eﬀ ects models was also assessed.18 Odds ratios (ORs) 
and 95% CIs were estimated. Between-site heterogeneity 
was assessed with likelihood ratio tests for variant by 
site interaction in a logistic regression analysis, and also 
by estimation of the I² statistic (a measure of the 
proportion of total variation in ORs between sites due to 
heterogeneity beyond chance).19
For variants with a minor allele frequency of less than 
0·5% (rare variants), although we estimated the 
proportion of carriers separately in patients and controls, 
no statistical tests were used to evaluate associations with 
PD because of insuﬃ  cient power. Instead, we collapsed 
information for rare variants, acknowledging that this 
has the potential limitation of mixing groups of variants 
with protective and risk eﬀ ects, and evaluated the 
association between the presence of any rare variant and 
PD in a logistic regression analysis adjusted by site.20 In 
an exploratory analysis, when collapsing data across 
variants, we also used the Sorts Intolerant From Tolerant 
(SIFT) prediction program21 to assess only those 
substitutions predicted to be not tolerated.
Haplotype analysis was done by use of score tests for 
association with adjustment for site;22 haplotypes of less 
than 0·5% frequency were not assessed. Any patient 
with a copy of the minor allele for any of the pathogenic 
variants that were noted in the study population 
(R1441C, R1441H, or G2019S) was excluded from all 
disease-association analyses to prevent confounding by 
the pathogenic variants; these patients were not 
excluded for any other portion of the analysis. Linkage 
disequilibrium between variants was assessed by use of 
r² values in study controls, separately for each series. 
Single variant associations with age at onset were 
assessed with linear regression models, adjusting for 
site in the white and Asian series; regression coeﬃ  cients 
and 95% CIs were estimated.
We adjusted for multiple testing by use of the single-
step minP method,23 with 10 000 within-site permu-
tations of outcome labels to assess the level of 
signiﬁ cance that controls the family-wise error rate at 
Exon Accession number cDNA Amin oacid Domain
(Continued from previous page)
chr12:38982935 26 ·· 3574A>G I1192V LRR
chr12:38984073 27 rs72546324 3647A>G H1216R LRR
chr12:38984109 27 rs80179604 3683G>C S1228T LRR
chr12:38984109 27 rs60185966 3683G>T S1228I LRR
chr12:38985860 28 rs4640000 3784C>G P1262A LRR
chr12:38988536 29 rs77018758 3960G>C/T R1320S ··
chr12:38988550 29 rs72546338 3974G>A R1325Q ··
chr12:38988687 29 rs17466213 4111A>G I1371V Roc
chr12:38988701 29 rs28365226 4125C>A D1375E Roc
chr12:38989178 30 rs7133914 4193G>A R1398H Roc
chr12:38989214 30 rs72546327 4229C>T T1410M Roc
chr12:38989243 30 rs113589830 4258G>A D1420N Roc
chr12:38989254 30 rs11175964 4269G>A K1423K Roc
chr12:38989275 30 rs111435410 4290C>T A1430A Roc
chr12:38989294 30 rs74163686 4309A>C N1437H Roc
chr12:38990503 31 rs33939927 4321C>T R1441C Roc
chr12:38990503 31 rs33939927 4321C>G R1441G Roc
chr12:38990504 31 rs34995376 4322G>A R1441H Roc
chr12:38990505 31 rs112998035 4323C>T R1441R Roc
chr12:38990506 31 ·· 4324G>C A1442P Roc
chr12:38990519 31 rs74681492 4337C>T P1446L Roc
chr12:38990530 31 rs111501952 4348G>A V1450I Roc
chr12:38990569 31 rs35363614 4387insA R1462fsX1468 Roc
chr12:38990584 31 ·· 4402A>G K1468E Roc
chr12:38990630 31 rs113431708 4448G>A R1483Q Roc
chr12:38994045 32 rs35507033 4541G>A R1514Q COR
chr12:38994128 32 rs33958906 4624C>T P1542S COR
chr12:38994170 32 rs17491187 4666C>A L1556I COR
chr12:38995335 33 rs721710 4793T>A V1598E COR
chr12:39000067 34 ·· 4838T>C V1613A COR
chr12:39000101 34 rs1427263 4872C>A G1624G COR
chr12:39000112 34 rs33949390 4883G>C R1628P COR
chr12:39000140 34 rs11176013 4911A>G K1637K COR
chr12:39000166 34 rs35303786 4937T>C M1646T COR
chr12:39000168 34 rs11564148 4939T>A S1647T COR
chr12:39000188 34 rs111503579 4959A>G L1653L COR
chr12:39001183 35 rs35801418 5096A>G Y1699C COR
chr12:39001350 35 rs79909111 5163A>G S1721S COR
chr12:39002106 36 rs11564176 5173C>T R1725X COR
chr12:39002116 36 ·· 5183G>T R1728L COR
chr12:39002116 36 rs145364431 5183G>A R1728H COR
chr12:39002455 37 rs111910483 5385G>T L1795F COR
chr12:39002527 37 rs10878371 5457T>C G1819G COR
chr12:39003324 38 ·· 5605A>G M1869V COR
chr12:39003325 38 rs35602796 5606T>C M1869T COR
chr12:39003329 38 ·· 5610G>T L1870F COR
chr12:39003339 38 ·· 5620G>T E1874X COR
chr12:39015100 39 rs77428810 5822G>A R1941H MAPKKK
chr12:39020430 41 ·· 6016T>C Y2006H MAPKKK
chr12:39020449 41 rs34015634 6035T>C I2012T MAPKKK
chr12:39020469 41 rs34637584 6055G>A G2019S MAPKKK
(Continues on next page)
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5%. After this adjustment, in the logistic regression 
disease-association analysis p≤0·0033 was judged to be 
signiﬁ cant in the white series and p≤0·0038 in the 
Asian series, whereas in the linear regression age at 
onset association analysis p≤0·0035 was judged to be 
signiﬁ cant in the white series and p≤0·0037 in the 
Asian series. The adjusted signiﬁ cance cutoﬀ  levels 
diﬀ ered between the white and Asian series because of 
the diﬀ erent number of tests undertaken in each series, 
and the diﬀ erent correlation structures between variants 
within them. For the fairly small Arab–Berber series, 
no adjustment for multiple testing was made, and as 
such the results were judged to be exploratory. All 
statistical analyses were done by use of SAS software 
(version 9.2) or S-Plus (8.0.1). 
Role of the funding source
The funding agencies did not play any part in the design 
of the study, collection, analysis, or interpretation of data, 
writing of the report, or the decision to submit the report 
for publication. The principal investigators (OAR and 
MJF) had access to all the data in this study. The 
corresponding author had ﬁ nal responsibility for the 
decision to submit. 
Results
Data were gathered from June, 2008, to October, 2010. 
23 sites from the GEO-PD Consortium, representing 
15 countries and ﬁ ve continents, agreed to participate 
in this study and contributed clinical data from 
8611 patients with PD and 6929 controls. We studied 
individuals in three series: white (6995 patients and 
5595 controls), Asian (1376 patients and 962 controls), 
and Arab–Berber (240 patients and 372 controls). 
Table 2 shows the demographics for each series, and 
webappendix p 5 shows the sample size breakdown for 
each site. 123 LRRK2 variants were selected for 
genotype analysis, but two (R793M and L2466H) did 
not assay by use of iPLEX and were dropped from the 
study. The other 121 variants were genotyped in the 
entire patient–control series (n=15 540); genotyping 
was successful in all individuals. Call rates for all 
genotypes in the series were greater than 95%. 
Deviation from HWE in the controls for each site (all 
p>0·05) was noted for LRRK2 N2081D in the Norwegian 
series and was attributable to two patients with a rare 
homozygous genotype; all patients were retained in the 
analysis. However, N289N and P1262A were excluded 
from the analysis of the Arab–Berber series because of 
signiﬁ cant variation from HWE due to an increased 
number of rare minor allele homozygotes, which might 
have been attributable to the consanguineous nature of 
the population.
Four of 121 LRRK2 exonic variants were nonsense, 
89 missense, and 28 silent. 48 variants, including four of 
the seven known pathogenic mutations, were not 
identiﬁ ed in the 15 540 patients and controls. For most of 
the variants, the pair-wise linkage disequilibrium was 
weak (r2<0·3), with higher values noted with D’ because 
of the low minor allele frequency for many of these 
variants (webappendix pp 6–17). 
Patients Controls
White series n=6995 n=5595
Age (years) 69 (12; 18–107) 65 (15; 19–107)
Men 4036 (58%) 2669 (48%)
Age at onset (years) 58 (12; 18–96) NA
Asian series n=1376 n=962
Age (years) 63 (13; 20–91) 59 (11; 23–98)
Men 681 (49%) 319 (33%)
Age at onset (years) 54 (12; 20–89) NA
Arab–Berber series n=240 n=372
Age (years) 66 (12; 27–87) 58 (11; 31–92)
Men 116 (48%) 190 (51%)
Age at onset (years) 57 (13; 20–82) NA
Data are mean (SD; range) or number (%), unless otherwise indicated. 
Information about sex was not available for six patients and eight controls in the 
Asian series, and 16 patients and 249 controls in the white series. Information 
about age was not available for eight patients and eight controls in the Asian 
series, 482 patients and 289 controls in the white series, and six patients and four 
controls in the Arab–Berber series. Information about the age at onset was not 
available for 14 patients in the Asian series and 801 patients in the white series. 
71 controls in the Taiwan case–control series overlapped with a previous study of 
R1628P.15 NA=not applicable.
Table 2: Characteristics of participants
Exon Accession number cDNA Amin oacid Domain
(Continued from previous page)
chr12:39020473 41 rs35870237 6059T>C I2020T MAPKKK
chr12:39020505 41 rs78029637 6091A>T T2031S MAPKKK
chr12:39026899 42 rs111739194 6187delCTCTA L2063X MAPKKK
chr12:39026953 42 rs33995883 6241A>G N2081D MAPKKK
chr12:39028521 43 rs10878405 6324G>A E2108E MAPKKK
chr12:39028553 43 rs12423862 6356C>T P2119L MAPKKK
chr12:39031648 44 rs111691891 6422C>T T2141M ··
chr12:39031736 44 rs34869625 6510C>A G2170G WD40
chr12:39031792 44 rs35658131 6566A>G Y2189C WD40
chr12:39036195 46 rs12581902 6782A>T N2261I WD40
chr12:39043509 48 rs113511708 7067C>T T2356I WD40
chr12:39043595 48 rs34778348 7153G>A G2385R WD40
chr12:39043597 48 rs33962975 7155A>G G2385G WD40
chr12:39043610 48 rs79546190 7168G>A V2390M WD40
chr12:39044912 49 rs78964014 7183G>A E2395K WD40
chr12:39044916 49 rs111272009 7187insGT T2356fsX2360 WD40
chr12:39044919 49 rs3761863 7190C>T M2397T WD40
chr12:39044953 49 rs60545352 7224G>A M2408I WD40
chr12:39047081 50 ·· 7397T>A L2466H WD40
chr12:39047119 50 rs55633591 7435A>G N2479D WD40
Chr12=chromosome 12. Roc=Ras in complex. COR=C-terminal of Ras. MAPKKK=mitogen-activated protein kinase 
kinase kinase. LRR=leucine-rich repeat. 
Table 1: LRRK2 exonic variants investigated in the study
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White series Asian series Arab–Berber series
Aminoacid MA MAF OR 
(95% CI)
p value MA MAF OR 
(95% CI)
p value MA MAF OR 
(95% CI)
p value
rs2256408 R50H G + + + ·· ·· ·· ·· G 1·7% 2·05 
(0·82–5·14)
0·13
rs10878245 L153L T 39·6% 0·98 
(0·91–1·06)
0·57 C 31·2% 1·04
(0·88–1·23)
0·65 C 47·1% 0·81
(0·55–1·19)
0·28
rs34594498 A419V T + + + T 1·9% 2·27
(1·35–3·83)
0·0011 ·· ·· ·· ··
rs7308720 N551K G 6·7% 0·88 
(0·79–0·98)
0·025 G 11·9% 0·73
(0·60–0·89)
0·0017 G 8·0% 0·83
(0·49–1·39)
0·47
rs10878307 I723V G 7·4% 0·94 
(0·84–1·04)
0·23 G 1·1% 1·36
(0·74–2·49)
0·32 G 9·0% 1·09
(0·68–1·75)
0·71
rs34410987 P755L ·· ·· ·· ·· T 0·6% 0·56 
(0·27–1·18)
0·13 ·· ·· ·· ··
rs58559150 Q923H C + + + ·· ·· ·· ·· C 0·9% 0·62
(0·13–2·99)
0·55
rs7966550 L953L C 12·8% 0·98 
(0·90–1·07)
0·66 C 17·6% 0·80 
(0·66–0·95)
0·012 C 12·4% 0·92
(0·60–1·41)
0·70
rs77018758 R1320S ·· ·· ·· ·· T 1·2% 1·20 
(0·69–2·11)
0·51 ·· ·· ·· ··
rs17466213 I1371V G + + + G + + + G 0·5% 4·45
(0·81–24·56)
0·086
rs7133914 R1398H A 6·6% 0·89 
(0·80–0·99)
0·034 A 11·5% 0·73 
(0·59–0·89)
0·0020 A 8·7% 1·00
(0·61–1·64)
1·00
rs11175964 K1423K A 6·6% 0·83 
(0·74–0·92)
0·0006 A 11·5% 0·75 
(0·62–0·92)
0·0064 A 5·4% 0·42
(0·21–0·86)
0·011
rs35507033 R1514Q A 0·9% 1·13 
(0·85–1·49)
0·41 ·· ·· ·· ·· A + + +
rs33958906 P1542S T 2·8% 0·90 
(0·77–1·06)
0·21 ·· ·· ·· ·· T 1·0% 2·27
(0·72–7·13)
0·16
rs1427263 G1624G C 34·7% 1·06 
(0·98–1·14)
0·15 A 46·7% 0·92 
(0·77–1·11)
0·40 C 31·7% 0·96
(0·67–1·39)
0·84
rs33949390 R1628P C + + + C 1·2% 0·62 
(0·36–1·07)
0·087 ·· ·· ·· ··
rs11176013 K1637K A 45·0% 1·02 
(0·94–1·11)
0·60 G 44·6% 0·96 
(0·80–1·16)
0·68 A 46·0% 1·07
(0·70–1·63)
0·76
rs35303786 M1646T C 1·6% 1·43 
(1·15–1·78)
0·0012 ·· ·· ·· ·· C + + +
rs11564148 S1647T A 29·9% 0·93 
(0·86–1·00)
0·048 A 28·3% 0·97 
(0·82–1·15)
0·73 A 27·6% 0·81
(0·55–1·19)
0·29
rs10878731 G1819G T 45·2% 1·06 
(0·98–1·15)
0·16 C 43·3% 0·99 
(0·83–1·19)
0·95 T 46·2% 1·07
(0·70–1·64)
0·75
rs33995883 N2081D G 2·6% 1·24 
(1·05–1·47)
0·013 G + + + G 4·7% 0·92
(0·49–1·73)
0·79
rs10878405 E2108E A 31·4% 0·96 
(0·89–1·03)
0·27 A 29·6% 1·01 
(0·85–1·20)
0·92 A 28·1% 0·75
(0·51–1·10)
0·14
rs35658131 Y2189C G + + + ·· ·· ·· ·· G 1·1% 4·48
(1·33–15·09)
0·012
rs3477838348 G2385R ·· ·· ·· ·· A 3·3% 1·73 
(1·20–2·49)
0·0026 ·· ·· ·· ··
rs33962975 G2385G G 15·7% 0·97 
(0·89–1·06)
0·49 G 1·8% 0·96 
(0·62–1·49)
0·85 G 8·4% 1·14
(0·7–0 1·83)
0·60
rs3761863 M2397T C 34·4% 1·06 
(0·98–1·14)
0·17 C 43·9% 0·88 
(0·73–1·05)
0·16 C 39·8% 1·33
(0·85–2·07)
0·21
ORs and p values result from logistic regression models, where adjustment was made for the site in the Asian and white series. ORs correspond to the presence of the MA. 
After adjustment for multiple testing, p≤0·0038 was judged to be signiﬁ cant in the Asian series, and p≤0·0033 was judged to be signiﬁ cant in the white series. No 
adjustment for multiple testing was made in the Arab–Berber series, for which p≤0·05 was judged to be signiﬁ cant. MA=minor allele. MAF=MA frequency. OR=odds ratio. 
+=a variant with a MAF of less than 0·5% and therefore not included in the logistic regression analysis. ··=a variant not noted in the series. 
Table 3: Common single LRRK2 variant associations with Parkinson’s disease
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Table 3 shows the results of the disease-association 
analysis of single LRRK2 variants. In the white series, 
signiﬁ cant associations with PD were noted for K1423K 
and M1646T. Figure 1 shows the country-speciﬁ c ORs 
and 95% CIs for the risk factor M1646T. The between-
site heterogeneity was low for M1646T (I2=0%, p=0·44) 
and moderate for K1423K (I2=34%, p=0·069) in the 
white series. 
In the Asian series, signiﬁ cant associations with PD 
were noted for LRRK2 A419V, N551K, R1398H, and 
G2385R (table 3). Figure 2 and ﬁ gure 3 show the 
country-speciﬁ c ORs and 95% CIs for A419V and 
G2385R, and for the N551K-R1398H-K1423K haplotype; 
between-site heterogeneity was very low for each of 
these associations in the Asian series (all I2=0%, all 
p≥0·42, webappendix p 18). Notably, LRRK2 R1628P 
was not associated with PD in the Asian series (table 3), 
with a non-signiﬁ cant protective eﬀ ect noted for this 
variant in the Taiwanese series (minor allele frequency 
3·8%, OR 0·56, 95% CI 0·32–1·01; p=0·054). Although 
not signiﬁ cant, the predicted risk eﬀ ect for R1628P was 
noted in the South Korean series, particularly at the 
Seoul site (0·2%, 2·47, 0·28–22·15; p=0·42). R1628P 
was not noted in the Japanese series. The previously 
suggested association of S1647T with PD in Asian 
populations14 was not supported by the results of our 
study (0·97, 0·82–1·15; p=0·73). 
In an exploratory analysis of the small Arab–Berber 
series, signiﬁ cant associations (p≤0·05, without 
correction for multiple testing) with PD were noted for 
K1423K and Y2189C (table 3). Larger Arab–Berber series 
are needed to conﬁ rm these associations.
For patients with available information (95%), results 
for the analysis of the association of single variants with 
disease in each series remained similar after adjustment 
for age and sex (webappendix p 19) and by use of an 
additive model (webappendix p 20). Eﬀ ect sizes were also 
similar after simultaneous adjustment for other variants 
that were signiﬁ cantly associated with PD in a particular 
series, and after adjustment for R1628P in the Asian 
series in which a previous association had been shown 
(webappendix p 21), providing evidence that these 
associations are independent of one another. With a 
random-eﬀ ects model for the white and Asian series, 
results were generally similar though slightly weaker 
(webappendix p 18) than those obtained with a ﬁ xed-
eﬀ ects model. 
Haplotype analysis showed a signiﬁ cant overall 
association with disease in the series of white (p=0·0016) 
and Asian (p=2×1–²⁴) individuals, but was non-signiﬁ cant 
in the Arab–Berber series (p=0·056). Haplotype 
associations seemed to be attributable to the variants 
independently implicated in disease (webappendix 
pp 22–24). When the three series were assessed together, 
LRRK2 N551K, R1398H, and K1423K, which are in 
strong linkage disequilibrium and constitute a common 
(>5% frequency) haplotype, were associated with a 
protective eﬀ ect (combined OR 0·82, 95% CI 0·72–0·94; 
p=0·0043; ﬁ gure 3). 
Results of all common single variant associations with 
age at onset are shown on webappendix p 25. We did not 
identify any associations that withstood multiple testing 
correction in the white and Asian series. In the 
Arab–Berber series, L153L was associated with age at 
onset roughly 4 years earlier (p=0·038), which needs 
conﬁ rmation in larger samples.
Table 4 provides a descriptive summary of rare variants 
(minor allele frequency <0·5%) in patients and controls in 
each series. The pathogenic variant R1441H was noted in 
an Asian patient, R1441C in only ten patients from the 
white series, and G2019S in all three series (table 4). The 
A
Japan (173 vs 95)
Korea (844 vs 587)
Taiwan (369 vs 300)
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Figure 2: Forest plots of LRRK2 variants A419V (A) and G2385R (B) in individuals with versus without 
Parkinson’s disease in the Asian series
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Figure 1: Forest plot of LRRK2 variant M1646T in individuals with versus without Parkinson’s disease in the 
white series
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median age of the eight control carriers of G2019S was 
64 years (range 48–76 years). Due to the strong confounding 
potential of these three variants on disease-association 
analyses, any patient with a copy of these risk alleles was 
excluded from the analysis. Other possible rare risk 
variants (E334K, R1325Q, and T1410M) and protective 
variants (A221V and A1151T) with diﬀ erences in frequency 
between patients with PD and controls were noted. When 
data for all rare variants were combined, the presence of 
any rare variant was not associated with PD in the white 
series (OR 1·01, 95% CI 0·81–1·25; p=0·95), Asian series 
(1·03, 0·57–1·85; p=0·92), or Arab–Berber series (0·78, 
0·28–2·20; p=0·64). Additionally, no association was noted 
in the white series (0·89, 0·55–1·43; p=0·62), Asian series 
(1·05, 0·37–2·99; p=0·93), or Arab–Berber series (no PD 
cases, two [<1%] controls, Fisher’s exact p=1·00) when the 
data were combined only for those variants predicted by 
use of the SIFT program to be not tolerated.24 Webappendix 
p 26 provides a summary of variants for which there were 
no carriers in any of the three series.
Discussion
The results of our study, one of the largest so far of the 
genetics of PD, show that a single gene, LRRK2, 
harbours many rare and common variants that confer 
susceptibility to PD in diverse populations (panel). 
Although population stratiﬁ cation is an inherent caveat 
of this type of large-scale collaborative eﬀ ort (and a 
potential limitation of the present study in the absence 
of genome-wide population control markers), these 
ﬁ ndings exemplify the conﬂ uence and independent 
eﬀ ects of rare and common variations on gene loci that 
have a major eﬀ ect in shaping both familial and 
sporadic disease.
About a third of variants we assessed were not identiﬁ ed 
in any study participant. These included four previously 
documented pathogenic mutations (LRRK2 N1437H, 
R1441G, Y1699C, and I2020T), showing that they are rare 
mutations in the population samples we assessed. 
26 variants were recorded at a frequency greater than 
0·5% in any of the three series, and only 13 were noted at 
a frequency greater than 0·5% in all three series. This 
ﬁ nding draws attention to the importance of studying 
genetic variability in large samples and in diﬀ erent ethnic 
groups, because frequencies and genetic eﬀ ects might 
vary substantially.26 
The newly identiﬁ ed associations warrant further 
discussion. M1646T in the COR (C-terminal of Ras) 
domain of LRRK2 was identiﬁ ed in the white series, 
and the eﬀ ect was consistent in many countries 
(ﬁ gure 1). This variant was not identiﬁ ed in participants 
of Asian descent and was rare in the series of 
Arab–Berber participants. LRRK2 A419V was 
consistently more common in patients than in controls 
in Asian sites (ﬁ gure 2). Although we cannot exclude 
the possibility of a non-coding element in linkage 
disequilibrium, the N-terminal region of the protein 
seems functionally relevant to disease development. 
LRRK2 M1646T is the ﬁ rst common-risk factor to have 
been identiﬁ ed in white populations, whereas A419V is 
now the third risk factor reported to be speciﬁ c to 
individuals of Asian ancestry, along with R1628P and 
G2385R.12,14,15 LRRK2 R1628P was not signiﬁ cantly 
associated with risk in our Asian series. This variant 
was common only in the Taiwanese series, in which a 
non-signiﬁ cant protective eﬀ ect was noted. Our inability 
to replicate the previously reported risk eﬀ ect of R1628P 
is likely to be due to a combination of the low frequency 
of this variant, natural sampling variation, and 
population heterogeneity, in view of the results of 
previous studies of ethnic Han Chinese populations (of 
note, G2385R did show association).14,15
The identiﬁ cation of a common three-variant 
haplotype (N551K-R1398H-K1423K) that seems to act in 
a protective manner (ﬁ gure 3) is also important. It 
suggests that the reduced penetrance that is noted in 
patients with LRRK2-associated parkinsonism might be 
due to variants acting in cis or trans with the pathogenic 
variant and that LRRK2 activity can be exploited to 
modify symptom onset in patients. Any future thera-
peutic strategies that lower risk in LRRK2-associated 
parkinsonism might protect against symptomatic onset 
in idiopathic PD.14,27 The previous report14 of a protective 
eﬀ ect with N551K and R1398H showed a reduced kinase 
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Figure 3: Forest plot of protective LRRK2 haplotype N551K-R1398H-K1423K in individuals with versus 
without Parkinson’s disease in the white, Asian, and Arab–Berber series
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White series Asian series Arab–Berber series
Aminoacid Patients (n=6995) Controls (n=5595) Patients (n=1376) Controls (n=962) Patients (n=240) Controls (n=372)
rs2256408 R50H 7 (0·10%) 1 (0·02%) ·· ·· + +
rs75054132 A75A ·· ·· ·· ·· 0 1 (0·27%)
rs33995463 L119P 21 (0·31%) 23 (0·44%) ·· ·· 0 2 (0·55%)
rs41286468 L122L 5 (0·08%) 7 (0·13%) ·· ·· ·· ··
rs112794616 A211V 4 (0·06%) 11 (0·21%) ·· ·· 0 1 (0·27%)
rs56108242 C228S 2 (0·03%) 2 (0·04%) ·· ·· ·· ··
rs28365216 N238I ·· ·· 3 (0·22%) 2 (0·22%) ·· ··
rs72546315 H275H 3 (0·04%) 2 (0·04%) ·· ·· 1 (0·43%) 0
rs17490713 N289N 1 (0·01%) 2 (0·04%) ·· ·· NA NA
rs41286466 A312A 26 (0·38%) 15 (0·28%) 1 (0·7%) 0 0 4 (1·10%)
rs78501232 E334K 14 (0·21%) 4 (0·07%) ·· ·· ·· ··
rs113065049 V366M 1 (0·02%) 0 ·· ·· ·· ··
rs34594498 A419V 5 (0·07%) 3 (0·06%) + + ·· ··
rs35847451 S416S 12 (0·18%) 16 (0·29%) ·· ·· ·· ··
rs75711334 L488L 1 (0·01%) 0 ·· ·· ·· ··
rs79996249 K544E 2 (0·03%) 2 (0·04%) ·· ·· ·· ··
rs78154388 S663P 2 (0·03%) 2 (0·04%) ·· ·· ·· ··
rs72546319 V674V 0 2 (0·04%) ·· ·· 0 1 (0·27%)
rs58559150 Q923H 1 (0·01%) 2 (0·04%) ·· ·· + +
rs75148313 S973N 1 (0·01%) 2 (0·04%) ·· ·· ·· ··
rs113217062 I1006M 1 (0·01%) 0 ·· ·· ·· ··
rs76535406 S1096C 0 2 (0·04%) ·· ·· ·· ··
rs35808389 L1114L 5 (0·07%) 1 (0·02%) ·· ·· ·· ··
rs74985840 A1151T 1 (0·01%) 5 (0·09%) ·· ·· ·· ··
rs80179604 S1228T 5 (0·07%) 4 (0·07%) ·· ·· ·· ··
rs4640000 P1262A 1 (0·01%) 1 (0·02%) ·· ·· NA NA
rs72546338 R1325Q 10 (0·15%) 3 (0·06%) 4 (0·29%) 1 (0·11%) ·· ··
rs17466213 I1371V 7 (0·10%) 4 (0·07%) 1 (0·07%) 0 + +
rs72546327 T1410M 5 (0·07%) 1 (0·02%) ·· ·· ·· ··
rs113589830 D1420N 1 (0·01%) 0 ·· ·· ·· ··
rs111435410 A1430A 2 (0·03%) 1 (0·02%) ·· ·· ·· ··
rs112998035 R1441R ·· ·· 1 (0·07%) 0 ·· ··
rs33939927* R1441C 10 (0·15%) 0 ·· ·· ·· ··
rs34995376* R1441H ·· ·· 1 (0·07%) 0 ·· ··
rs74681492 P1446L ·· ·· 10 (0·74%) 6 (0·62%) ·· ··
rs111501952 V1450I ·· ·· 2 (0·15%) 1 (0·11%) ·· ··
rs113431708 R1483Q 1 (0·01%) 0 ·· ·· ·· ··
rs35507033 R1514Q + + ·· ·· 0 1 (0·27%)
rs33949390 R1628P 7 (0·10%) 0 + + ·· ··
rs35303786 M1646T + + ·· ·· 3 (1·25%) 2 (0·54%)
rs111503579 L1653L 2 (0·03%) 1 (0·02%) 4 (0·30%) 9 (0·93%) ·· ··
rs79909111 S1721S 1 (0·02%) 1 (0·02%) ·· ·· ·· ··
rs263192805 R1728H 1 (0·01%) 3 (0·05%) ·· ·· ·· ··
rs35602796 M1869T 5 (0·07%) 2 (0·04%) ·· ·· ·· ··
rs77428810 R1941H 2 (0·03%) 1 (0·02%) ·· ·· ·· ··
rs34637584* G2019S 48 (0·71%) 3 (0·06%) 1 (0·07%) 1 (0·11%) 72 (30·25%) 4 (1·10%)
rs111739194 L2063STOP 1 (0·02%) 2 (0·04%) ·· ·· ·· ··
rs33995883 N2081D + + 2 (0·15%) 0 + +
rs34869625 G2170G 20 (0·30%) 21 (0·39%) ·· ·· 1 (0·60%) 0
rs35658131 Y2189C 1 (0·01%) 2 (0·04%) ·· ·· + +
rs113511708 T2356I 7 (0·1%) 5 (0·09%) ·· ·· ·· ··
(Continues on next page)
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activity for the R1398H variant, suggesting this Roc 
domain substitution might be the most likely functional 
allele on the haplotype. 
Although the results of our study have identiﬁ ed an 
association of PD only with common variants, they also 
draw attention to the many rare variants in LRRK2 that 
could contribute to disease risk. Genetic loci that 
contribute to disease risk might do so through variants 
that span the whole range of minor allele frequencies, 
from rare mutations to frequent single nucleotide 
polymorphisms.28 Despite the very large sample size, we 
noted only three of seven previously described pathogenic 
LRRK2 mutations. Hence, the search for mutations 
contributing to familial PD should include an analysis of 
single pedigrees, with further assessment in very large 
population studies. Single pedigrees might result in 
some false-positive results, which can be ﬁ ltered out 
with large population samples. For example, two variants 
(I1371V and T2356I) have been proposed as pathogenic 
and to account for the clinical and functional features of 
LRRK2-associated parkinson ism.29,30 How ever, in our 
study, both variants were noted in patients and controls 
at the same frequency (table 4). Conversely, we noted 
other possible rare risk (E334K, R1325Q, and T1410M) 
and protective (A211V and A1151T) variants; however, 
because of their low frequency, large meta-analytical 
approaches are necessary to deﬁ ne their roles fully. 
In this study, we focused on exonic variants because all 
pathogenic variants identiﬁ ed in LRRK2 so far have been 
single nucleotide missense changes. However, silent, 
synonymous variants were also included because they 
can result in alternative splicing and, since protein 
translation is a function of codon use and transfer RNA 
abundance, could aﬀ ect the rate of protein domain 
folding and secondary modiﬁ cations.31 Neither copy 
number variants nor other risk factors in non-coding 
regions that regulate LRRK2 expression or alter splicing 
were assessed in our study. 
As new loci for susceptibility to diverse diseases are 
continuously being discovered in genome-wide 
association and whole-genome sequencing studies, the 
results of our study show the importance of revisiting 
loci at which rare or common variants have been 
White series Asian series Arab-Berber series
Aminoacid Patients (n=6995) Controls (n=5595) Patients (n=1376) Controls (n=962) Patients (n=240) Controls (n=372)
(Continued from previous page)
rs79546190 V2390M 1 (0·01%) 1 (0·02%) ·· ·· ·· ··
rs78964014 E2395K 1 (0·01%) 0 ·· ·· ·· ··
rs60545352 M2408I 1 (0·01%) 0 ·· ·· 0 2 (0·54%)
Data are number (%). PD=Parkinson’s disease. +=a variant that was noted with a minor allele frequency of at least 0·5% and as such was analysed as a common variant. 
··=a variant that was not noted in the series. NA=a variant that  was out of the Hardy–Weinberg equilibrium in the speciﬁ c series. *Pathogenic variants for which the 
number (%) of carriers is summarised for the entire sample; any carriers of these pathogenic variants were removed from the summaries provided for each of the remaining 
non-pathogenic variants.
Table 4: LRRK2 rare variants
identiﬁ ed, since they could harbour many more 
independent signals of genetic risk in diﬀ erent 
populations.25,32,33 Furthermore, LRRK2 sequencing 
studies in under-represented populations (eg, from 
South America, sub-Saharan Africa, Middle East, and 
western Asia) will undoubtedly show novel ethnic-
group-speciﬁ c risk variants and could clarify the role of 
variants that were rare or absent in our study. LRRK2 
variants, including novel exonic variants, were reported 
as part of the 1000 Genome Project, lending support to 
this hypothesis.34
Large-scale parallel resequencing (targeted genomic 
capture of the speciﬁ c regions—eg, gene-speciﬁ c, exome, 
transcriptome, and whole-genome sequencing) is likely 
Panel: Research in context
Systematic review
We searched PubMed with the terms “LRRK2” and “Genetics 
Parkinson’s disease” and identiﬁ ed all LRRK2 coding variations 
reported up until April 1, 2010. We also contacted our global 
network of collaborators and the members of the Genetic 
Epidemiology Of Parkinson’s Disease (PD) Consortium for 
unreported variants.
Interpretation
By focusing on the role of LRRK2 variation in PD, we have 
identiﬁ ed a common risk factor in the white population 
(M1646T), the third common risk factor in Asian 
populations (A419V), and a common global protective 
haplotype (N551K-R1398H-K1423K). This work 
complements the meta-analysis of PD genome-wide 
association,25 which suggests a possible association at the 
LRRK2 locus. We deﬁ ne some of the genetic variation that is 
likely to be contributing to the association noted in recent 
genome-wide association eﬀ orts and nominate potential 
functionally and clinically relevant variants. We show 
modulation of the underlying toxic eﬀ ect is possible 
because of the protective nature of the 
N551K-R1398H-K1423K haplotype. The identiﬁ cation 
of common variants that aﬀ ect risk clearly shows a 
greater role for LRRK2 in idiopathic disease than 
previously thought.
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to identify many more variants in candidate genes that 
might predispose to PD. Characterisation of each variant 
will require this type of collaborative international eﬀ ort 
to deﬁ ne their pathogenicity, frequency in diﬀ erent 
populations, and contribution to disease pathogenesis 
through genotype–phenotype assessment. 
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